Trials / Completed
CompletedNCT00160316
Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination
Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 454 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate endometrial safety of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone | p.o. daily |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-09-12
- Last updated
- 2008-03-12
Locations
22 sites across 4 countries: Croatia, Poland, Romania, Ukraine
Source: ClinicalTrials.gov record NCT00160316. Inclusion in this directory is not an endorsement.